Home > Products > HS-452 011

Nucleocapsid CoV-2 antibody - HS-452 011

CoV2 protein N packages the viral genome RNA
Mouse monoclonal purified IgG
Cat. No.: HS-452 011
Amount: 200 µl
Price: $415.00
Cat. No. HS-452 011 200 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: 1 : 1000 gallery  
IP: not tested yet
ICC: yes gallery  
IHC: 1 : 1000 gallery  
IHC-P: 1 : 1000 gallery  
ELISA: yes (see remarks) gallery  
Clone 4A8
Subtype IgG2b (κ light chain)
Immunogen Recombinant protein corresponding to AA 1 to 419 from SARS-Cov-2 Nucleocapsid protein (UniProt Id: P0DTC9)
Epitop AA 16 to 25 from SARS-Cov-2 Nucleocapsid protein (UniProt Id: P0DTC9)
Specificity Specific for nucleocapsid from SARS-CoV2
Remarks

ELISA: This antibody is suitable as capture antibody for sandwich-ELISA with cat. no. 452 111BT as detector antibody.
Data sheet hs-452_011.pdf

References for Nucleocapsid CoV-2 - HS-452 011

Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19.
Radke J, Meinhardt J, Aschman T, Chua RL, Farztdinov V, Lukassen S, Ten FW, Friebel E, Ishaque N, Franz J, Huhle VH, et al.
Nature neuroscience (2024) 273: 409-420. HS-452 011 IHC; tested species: human
Assessing and improving the validity of COVID-19 autopsy studies - A multicentre approach to establish essential standards for immunohistochemical and ultrastructural analyses.
Krasemann S, Dittmayer C, von Stillfried S, Meinhardt J, Heinrich F, Hartmann K, Pfefferle S, Thies E, von Manitius R, Aschman TAD, Radke J, et al.
EBioMedicine (2022) 83: 104193. HS-452 011 IHC-P; tested species: human
Distinct tissue niches direct lung immunopathology via CCL18 and CCL21 in severe COVID-19.
Mothes R, Pascual-Reguant A, Koehler R, Liebeskind J, Liebheit A, Bauherr S, Philipsen L, Dittmayer C, Laue M, von Manitius R, Elezkurtaj S, et al.
Nature communications (2023) 141: 791. HS-452 011 IHC-P; tested species: human
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.
Stanelle-Bertram S, Beck S, Mounogou NK, Schaumburg B, Stoll F, Al Jawazneh A, Schmal Z, Bai T, Zickler M, Beythien G, Becker K, et al.
Cell reports. Medicine (2023) 49: 101152. HS-452 011 IHC-P; tested species: human
Post-mortem histopathology of pituitary and adrenals of COVID-19 patients.
Fitzek A, Gerling M, Püschel K, Saeger W
Legal medicine (Tokyo, Japan) (2022) 57: 102045. HS-452 011 IHC-P; tested species: human
Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls.
Matschke J, Lahann H, Krasemann S, Altmeppen H, Pfefferle S, Galliciotti G, Fitzek A, Sperhake JP, Ondruschka B, Busch M, Rotermund N, et al.
Frontiers in neurology (2022) 13: 908081. HS-452 011 IHC-P; tested species: human
Cat. No.: HS-452 011
Amount: 200 µl
Price: $415.00

Detection of SARS-CoV-2 nucleocapsid protein in brains of SARS-CoV-2 infected and non-infected K18-hACE2 transgenic mice.

Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19.
Radke J, Meinhardt J, Aschman T, Chua RL, Farztdinov V, Lukassen S, Ten FW, Friebel E, Ishaque N, Franz J, Huhle VH, et al.
Nature neuroscience (2024) 273: 409-420. HS-452 011 IHC; tested species: human
Assessing and improving the validity of COVID-19 autopsy studies - A multicentre approach to establish essential standards for immunohistochemical and ultrastructural analyses.
Krasemann S, Dittmayer C, von Stillfried S, Meinhardt J, Heinrich F, Hartmann K, Pfefferle S, Thies E, von Manitius R, Aschman TAD, Radke J, et al.
EBioMedicine (2022) 83: 104193. HS-452 011 IHC-P; tested species: human
Distinct tissue niches direct lung immunopathology via CCL18 and CCL21 in severe COVID-19.
Mothes R, Pascual-Reguant A, Koehler R, Liebeskind J, Liebheit A, Bauherr S, Philipsen L, Dittmayer C, Laue M, von Manitius R, Elezkurtaj S, et al.
Nature communications (2023) 141: 791. HS-452 011 IHC-P; tested species: human
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males.
Stanelle-Bertram S, Beck S, Mounogou NK, Schaumburg B, Stoll F, Al Jawazneh A, Schmal Z, Bai T, Zickler M, Beythien G, Becker K, et al.
Cell reports. Medicine (2023) 49: 101152. HS-452 011 IHC-P; tested species: human
Post-mortem histopathology of pituitary and adrenals of COVID-19 patients.
Fitzek A, Gerling M, Püschel K, Saeger W
Legal medicine (Tokyo, Japan) (2022) 57: 102045. HS-452 011 IHC-P; tested species: human
Young COVID-19 Patients Show a Higher Degree of Microglial Activation When Compared to Controls.
Matschke J, Lahann H, Krasemann S, Altmeppen H, Pfefferle S, Galliciotti G, Fitzek A, Sperhake JP, Ondruschka B, Busch M, Rotermund N, et al.
Frontiers in neurology (2022) 13: 908081. HS-452 011 IHC-P; tested species: human
WB
ICC
ICC
IHC
IHC
IHC-P
IHC-P
IHC-P
ELISA
ELISA
Background

The severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2) is an enveloped positive-sense single stranded RNA virus that has been identified in the beginning of 2020 (1). It infects human host cells by docking via its spike protein (S) to the ACE2 surface receptor (2) and can cause mild to very severe and even deadly Covid-19 courses (3).
The very abundant Nucleocapsid or N-protein packages the viral RNA (4) and shares only little homology to other abundant members of the coronavirus family like NL63, 229E, HKU1 or OC43. This characteristic makes it a suitable target to discriminate between Covid-19 and other coronavirus infections.
Protocols for HS-452 011
WB
IHC
IHC-P
Other products for this target